Evidence map›Paper›PMID 41926748›Full record

ArticleRheumatology (Oxford, England)2026

Structural alterations in PPP1R13L, SAE1, ATP5A1 and PCK2 disrupt NF-κB signalling and mitochondrial metabolism in primary dermal fibroblasts in systemic sclerosis.

Jingya Li, Daniel Abegg, Liliana Malinovska, Michał Rudnik, Oliver Distler, Przemysław Błyszczuk, Paola Picotti, Gabriela Kania

Abstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jingya LiDepartment of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Daniel AbeggDepartment of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Liliana MalinovskaInstitute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
Michał RudnikDepartment of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Oliver DistlerDepartment of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0546-8310
Przemysław BłyszczukDepartment of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Paola PicottiInstitute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
Gabriela KaniaDepartment of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-3788-4594

Funding

Swiss National Science Foundations 310030_175663Swiss National Science Foundations 310030_20770
6 · The paper itself

Abstract

objectiveSSc is a proteopathy with limited diagnostic and therapeutic options. This study aimed to uncover structural protein alterations in dermal fibroblasts from diffuse cutaneous (dc)SSc patients using a novel method: limited proteolysis-MS (LiP-MS).

methodsUntreated primary dermal dcSSc fibroblasts and healthy control (HC) fibroblasts were analysed by LiP-MS to detect proteome-wide conformational changes. Fibroblasts were further stimulated with inflammatory cytokines: TNFα, IL-1β, TGF-β and IL-17A, highly relevant in SSc. NF-κB activity was assessed via luciferase reporter assays, while immunoblotting measured total and phosphorylated p65. ATP levels were quantified with luminescent assays, and caspase-3/7 activity was used to assess apoptosis.

resultsLiP-MS identified 53 263 peptides corresponding to 5310 proteins, of which 41 showed significant conformational differences in SSc fibroblasts compared with HCs. Four proteins mapped to NF-κB signalling, while eight were linked to metabolism. Notably, structural changes were detected near functional domains of PPP1R13L and SAE1 (NF-κB regulators) and in ATP5A1 and PCK2 (mitochondrial metabolism). Functional analyses showed that TGF-β stimulation modulated NF-κB activity and the phospho-p65/total-p65 ratio, while IL-17A stimulation induced more pronounced ATP alterations in SSc fibroblasts compared with HCs.

conclusionNovel method LiP-MS successfully revealed protein conformational changes in SSc fibroblasts, particularly in domains central to NF-κB signalling and metabolic regulation. LiP-MS represents a powerful proteome-wide strategy for mapping protein structural perturbations and identifying candidate proteins and pathways for future mechanistic investigation, thereby offering a unique opportunity to connect protein conformational changes with cellular dysfunction and to potentially guide precision therapeutic approaches in SSc.

Indexed as

FibroblastsMitochondriaNF-kappa BScleroderma, SystemicCells, CulturedHumansInterleukin-17Mitochondrial Proton-Translocating ATPasesSignal TransductionATP5F1A protein, humanInterleukin-17Mitochondrial Proton-Translocating ATPasesNF-kappa Blimited proteolysis coupled with MSmetabolic regulationNF-κB signallingprimary dermal fibroblastsprotein conformational changesprotein functional domainsSSc

Identifiers

PMID41926748
PMCPMC13531016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.